文献速递炎症性肠病

综述:炎症性肠病的新型疗法——面向临床医生的更新

Review article: Novel therapies in inflammatory bowel disease - An update for clinicians.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-01

本综述面向临床医生,系统检索已发表文献与主要会议摘要中的克罗恩病和溃疡性结肠炎III期安慰剂对照及活性对照试验,梳理新近获批与在研疗法(选择性Janus激酶抑制剂、鞘氨醇-1受体调节剂、p19白细胞介素(IL)-23抑制剂等)的疗效,并讨论治疗策略中的序贯与时机等关键挑战。作者指出,长期扩展研究、真实世界研究与头对头试验的数据仍需积累,以更好地指导长期安全性与最优序贯治疗。

要点

  • 选择性Janus激酶抑制剂、鞘氨醇-1受体调节剂与p19 IL-23抑制剂在克罗恩病和溃疡性结肠炎中均显示改善患者结局。
  • 头对头研究增进了对新型疗法(尤其是IL-23抑制剂)何时及如何最优使用的理解。
  • 早期有效治疗、联合治疗与序贯策略等新策略持续改变IBD诊疗;长期安全性仍需长期扩展与真实世界数据。

核心结论

  • 新近获批的新型疗法扩大了IBD的药物治疗选择,但长期安全性数据与最优序贯治疗仍需长期扩展研究、真实世界研究与头对头试验进一步提供依据。

研究设计与样本

  • 综述:全面检索已发表文献与主要会议摘要,纳入克罗恩病和溃疡性结肠炎的III期安慰剂对照及活性对照试验。

主要发现

  • 选择性Janus激酶抑制剂、鞘氨醇-1受体调节剂与p19白细胞介素(IL)-23抑制剂的已获批疗法数据在克罗恩病和溃疡性结肠炎中均显示改善患者结局。
  • 进一步的头对头研究增进了对新型疗法(尤其是IL-23抑制剂)何时及如何最优使用的理解。
  • 在研治疗选择与早期有效治疗、联合治疗、序贯影响等新策略的数据持续改变IBD诊疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,仍需长期扩展研究、真实世界研究与头对头试验的数据,以更好地指导IBD患者的长期安全性与最优序贯治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several new treatments including small molecules and biologics have been approved for the treatment of inflammatory bowel diseases in recent years. Clinicians and patients now have a wide variety of therapeutic options to choose from and these novel therapies provide several advantages including oral administration, lower immunogenicity, better selectivity and arguably better safety profiles. An increase in treatment options has increased the complexity of decision-making. Both patients and clinicians have had to become rapidly familiar with efficacy of new medications balanced against a range of pre-initiation requirements, dosing schedules and adverse event profiles. AIMS: To provide a simple guide to practising clinicians on recently approved and emerging therapies and address key challenges around treatment strategies such as optimal sequencing and timing of treatment. METHODS: We comprehensively searched the published literature and major conference abstracts to identify phase III placebo-controlled and active comparator trials for Crohn's disease and ulcerative colitis. RESULTS: Data for recently approved therapies including selective Janus kinase inhibitors, sphingosine-1 receptor modulators and p19 interleukin (IL)-23 inhibitors have demonstrated improved patient outcomes in both Crohn's disease and ulcerative colitis. Further comparative head-to-head studies have improved our understanding of when and how to optimally use newer therapies, specifically for IL-23 inhibitors. Data for emerging treatment options and novel treatment strategies such as early effective treatment, combinations of treatments and implications for sequencing are continuing to transform IBD care continually. CONCLUSIONS: Recently approved novel therapies have expanded the range of medical options available to treat IBD. However, further data from long-term extension studies, real-world studies and head-to-head trials are warranted to better inform the long-term safety and optimal sequencing of treatments for patients living with IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Noor NM, Bourke A, Subramanian S, et al. Review article: Novel therapies in inflammatory bowel disease - An update for clinicians. Aliment Pharmacol Ther. 2024. PMID: 39403052. doi:10.1111/apt.18294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。